Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23922551 | 1.00 | POLRMT (0.42) | POLRMTTMPRSS2 | |
| SCHEMBL20819189 | 0.92 | POLRMT (0.41) | POLRMTTMPRSS2 | |
| SCHEMBL25821367 | 0.84 | ACVRL1 (0.34) | POLRMT | |
| SCHEMBL25821383 | 0.83 | TMPRSS2 (0.37) | POLRMTTMPRSS2 | |
| SCHEMBL20819140 | 0.83 | POLRMT (0.64) | POLRMTTMPRSS2 | |
| SCHEMBL24120051 | 0.83 | POLRMT (0.64) | POLRMTTMPRSS2 | |
| Phosphoric Acid SCHEMBL20819141 | 0.81 | POLRMT (0.41) | POLRMTTMPRSS2 | |
| SCHEMBL22372336 | 0.81 | TMPRSS2 (0.40) | POLRMTTMPRSS2 | |
| SCHEMBL20834797 | 0.81 | TMPRSS2 (0.40) | POLRMTTMPRSS2 | |
| SCHEMBL22393486 | 0.81 | TMPRSS2 (0.40) | POLRMTTMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111542531-B | Substituted nucleosides, nucleotides and analogues thereof | 詹森生物制药有限公司 | 2024-07-19 | — | — | CN | disclosed |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20210395288-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | JANSSSEN BIOPHARMA, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210395288-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | JANSSSEN BIOPHARMA, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| EP-3684782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019053696-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019053696-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | POLRMT 79/4885TMPRSS2 664/4885 |
| US-11773126-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | POLRMT 48/4885TMPRSS2 867/4885 |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | POLRMT 139/4885TMPRSS2 145/4885 |
| US-20210395288-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | POLRMT 79/4885TMPRSS2 664/4885 |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | POLRMT 48/4885TMPRSS2 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.